SMPDB
  • Browse SMPDB
    • Pathways
    • Table of Primary Pathways
    • Compounds
    • Proteins
  • Search
    • TextQuery Search Instructions
    • SMP-MAP Advanced Search
    • ChemQuery Structure Search
    • Molecular Weight Search
    • Sequence Search
  • About
    • About SMPDB
    • Release Notes
    • Citing SMPDB
    • Statistics
    • Other Databases
    • Pathway Legend
    • Pathway Category Definitions
  • PathWhiz
  • Downloads
  • Contact Us
Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Loading Pathway...

Error: Pathway image not found.
Hide
  • Description
  • Highlight
  • Analyze
  • Downloads
  • Settings
Pathway Description

Arbekacin Action Pathway

Homo sapiens
Drug Action Pathway
Created: 2014-04-26
Last Updated: 2025-01-29
Arbekacin, trade name Habekacin, is an aminoglycoside antibiotic derived from dibekacin that inhibits bacterial protein synthesis. Arbekacin is prescribed to patients with sepsis and pneumonia resulting from MRSA. Arbekacin binds the bacterial 50S and 30S ribosomal subunit proteins and prevents the formation of the initiation complex with messenger RNA. More specifically, Arbekacin binds four nucleotides of the 16S rRNA and a single amino acid of protein S12. This interferes with the decoding site in the vicinity of nucleotide 1400 in 16S rRNA of the 30S subunit. This region interacts with the wobble base of the anticodon of tRNA. This causes interference of the initiation complex, misreading of mRNA so that incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides, and the breakup of polysomes into nonfunctional monosomes. Arbekacin is effective at treating Gram-positive bacteria like Staphylococcus aureus and Staphylococcus epidermidis and Gram-negative bacteria such as Pseudomonas aeruginosa.
References

Arbekacin Pathway References

Matsumoto T: Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.

Pubmed: 25298740

Sader HS, Rhomberg PR, Farrell DJ, Jones RN: Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.

Pubmed: 25801559

Matsumoto T: Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.

Pubmed: 25298740
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
No Proteins Present
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
No Proteins Present
Downloads
SVG Image
Simple SVG Image
Large Font SVG Image
Simple Large Font SVG Image
Greyscale SVG Image
BioPAX
SBGN
SBML
PWML
PNG Image
All files (.zip)
Settings